mRNA melanoma vaccine cuts metastasis risk by 60%, may soon win approval

Oncologist Prof. Piotr Rutkowski reported that an mRNA vaccine against melanoma, used alongside standard immunotherapy, reduces the risk of distant metastasis by 60% compared to standard treatment alone. Survival curves are approaching 100% recurrence-free rates. He said the groundbreaking drug could receive market approval in the near future.